June 12, 2024

3 Minutes
Medicine

Sage Therapeutics Phase 2 SURVEYOR Study Reinforces Cognitive Impact of Huntington’s Disease

Sage Therapeutics announced topline results from the Phase 2 SURVEYOR Study. The study met its primary endpoint demonstrating a statistically significant difference as measured by the HD-Cognitive Assessment Battery (HD-CAB) composite score at baseline between...
Read More